Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (2895)	11/19/1997 9:02:00 PM
From: Oliver & Co	Read Replies (2) \| Respond to of 6136

First let me say that I have not yet seen the studies. Margaret Fischl, told us about it Saturday. So I first have to read them. I consider every antiretroviral useful, some more than others. If what she said is the way she said it, then I will not use AZT to start naive patients. But you have to remember that many times therapy must be changed because of toxicities, or failure. So, there will continue to be a big place for AZT. Besides, it has the best CNS penetration. Believe it or not, I still use Cryx (2nd choice)and usually in combo with rescriptor. With Viracept you may use, d4T-3TC, or ddi-3TC, or ddi-d4T, or even Viramune-or Rescriptor with any nrti.